Tuesday, Johnson & Johnson (NYSE:JNJ) released better-than-expected earnings for its fourth quarter of 2023.
It reported quarterly adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus of $2.28. Sales increased 7.3% Y/Y to $21.4 billion, beating the consensus of $20.99 billion.
On Tuesday, the stock closed 1.67% lower at $159.76, with a session volume of 9.147 million, compared to the average volume (100 day) of 6.798 million, according to data from Benzinga Pro.
In the initial year following its $16.6 billion acquisition of Abiomed, Johnson & Johnson MedTech has experienced significant returns.
The company reported a notable ...